Hrdlicka Michal, Zedkova Iveta, Blatny Marek, Urbanek Tomas
Department of Child Psychiatry, Charles University, Prague, Czech Republic.
Neuro Endocrinol Lett. 2009;30(2):256-61.
The aim of the study was to assess weight changes associated with certain atypical (AAP) and typical (TAP) antipsychotic drugs in patients with early-onset schizophrenia and other related psychotic disorders.
Our retrospective study included 109 patients (52 boys, 57 girls) with a mean age of 15.8 +/- 1.6 years. The patients were evaluated based to their medical records prior to starting therapy, and then after 1, 3, and 6 weeks of treatment.
During the first week of treatment, the AAP group (n = 85; risperidone, olanzapine, ziprasidone, and clozapine) gained 1.5% of baseline weight whereas the TAP group (n = 24; haloperidol, perphenazine, and sulpiride) gained only 0.2% (p = 0.049). Differences in relative changes between the two groups were not significant at weeks 3 and 6. Expressed as absolute values, patients in our sample gained an average of 3.4 kg (SD 3.2) on AAP and 2.0 kg (SD 3.9) on TAP during 6 weeks of treatment (p = 0.335). Only the risperidone, olanzapine, and clozapine groups had sufficient numbers of patients to allow a comparison at the endpoint of the study (week 6). The patients gained, on average, 3.6 kg (SD 2.6) on risperidone, 4.4 kg (SD 2.5) on olanzapine, and 2.1 kg (SD 4.0) on clozapine during the six weeks of treatment (p = 0.286).
In our study, we did not find a difference in weight gain between the AAP and TAP groups, as large as has been described in the literature. It also seems plausible that the unique and variable weight changes associated with individual AAPs in the pediatric population are different from those observed in the adult population.
本研究旨在评估早发性精神分裂症及其他相关精神障碍患者使用某些非典型抗精神病药物（AAP）和典型抗精神病药物（TAP）后的体重变化。
我们的回顾性研究纳入了109例患者（52名男孩，57名女孩），平均年龄为15.8±1.6岁。在开始治疗前以及治疗1周、3周和6周后，根据患者的病历对其进行评估。
在治疗的第一周，AAP组（n = 85；利培酮、奥氮平、齐拉西酮和氯氮平）体重增加了基线体重的1.5%，而TAP组（n = 24；氟哌啶醇、奋乃静和舒必利）仅增加了0.2%（p = 0.049）。在第3周和第6周时，两组相对变化的差异不显著。以绝对值表示，我们样本中的患者在6周治疗期间，使用AAP平均体重增加3.4 kg（标准差3.2），使用TAP平均体重增加2.0 kg（标准差3.9）（p = 0.335）。只有利培酮、奥氮平和氯氮平组有足够数量的患者，以便在研究终点（第6周）进行比较。在六周的治疗期间，使用利培酮的患者平均体重增加3.6 kg（标准差2.6），使用奥氮平的患者平均体重增加4.4 kg（标准差2.5），使用氯氮平的患者平均体重增加2.1 kg（标准差4.0）（p = 0.286）。
在我们的研究中，我们没有发现AAP组和TAP组之间的体重增加差异如文献中所描述的那么大。儿科人群中与个体AAP相关的独特且多变的体重变化似乎也与成人人群中观察到的不同，这似乎也是合理的。
